A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
Sponsor: Energenesis Biomedical Co., Ltd.
Listed as NCT05930210, this PHASE3 trial focuses on Diabetes Mellitus and Diabetic Foot Ulcer and remains actively recruiting participants. Sponsored by Energenesis Biomedical Co., Ltd., it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE3
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Energenesis Biomedical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .